GH Research PLC (NASDAQ: GHRS), a Dublin-based clinical-stage biotech company reported financial results for the first quarter ended March 31, 2023. The company is developing a proprietary 5-MeO-DMT formulation primarily targeting Treatment-Resistant Depression (TRD).
Total cash position (cash, cash equivalents, other financial assets and marketable securities) of $246.1 million as of March 31, 2023, compared to $251.7 million as of Dec. 31, 2022.
Net loss of $10.9 million, or $0.210 loss per share, for the quarter ended March 31, 2023, compared to $5.8 million, or $0.111 loss per share, for the same quarter in 2022
Quarterly R&D and G&A expenses of $7.3 million and $3.1 million respectively, compared to $4.7 million and $3.3 million for the same …